Applying precision medicine to find a better solution

Alzheon’s valiltramiprosate/ALZ-801 is currently the only oral anti-amyloid treatment in Phase 3 testing for Alzheimer’s disease. We believe that valiltramiprosate has the potential to significantly slow or stop disease progression, and even prevent the onset of clinical symptoms.

Development of valiltramiprosate, a well-tolerated new treatment, is based on ten years of Alzheon research into the biology of Alzheimer’s. Safety profile in valiltramiprosate studies remains favorable & consistent with prior data in over 3,000 AD patients, with no increased risk of vasogenic brain edema.

Using our pioneering precision medicine approach, we are initially focusing our development on the highest risk patients with two copies of the APOE4 gene (APOE4/4 homozygotes), who are predicted to benefit most from the valiltramiprosate treatment. Future trials will expand treatment to patients with only one copy of the APOE4 gene, and ultimately to prevention of onset of Alzheimer’s.

About valiltramiprosate

For privacy reasons Vimeo needs your permission to be loaded. For more details, please see our Privacy Policy.

Wall Street analyst Robyn Karnauskas of Truist Securities discussing with Alzheon management team new data and therapeutic potential of valiltramiprosate.

Alzheon company profile

Working to quickly bring valiltramiprosate to market as the first oral disease modifying Alzheimer’s treatment

• Founded in 2013 by Martin Tolar, MD, PhD
• Developing an investigational oral anti-amyloid oligomer treatment valiltramiprosate
• Completed Phase 2 biomarker open-label study supports disease modifying potential of valiltramiprosate
• APOLLOE4 Phase 3 evaluating valiltramiprosate oral tablet enrolled, topline data anticipated 3Q 2024
• Received $51M in grants from National Institute on Aging to partially fund APOLLOE4 Phase 3 trial

Valiltramiprosate/ALZ-801 acts upstream of anti-amyloid drugs in AD

Alzheon publications: Tolar (2024) Int J Mol Sci; Tolar (2021) Int J Mol Sci; Tolar (2020) Alzheimers Res Ther; Tolar (2019) Alzheimers Dement

Validated precision medicine approach supported by experts

Received $51M in grants from National Institute on Aging to support APOLLOE4 Phase 3 study
Prominent global Scientific Advisory Board
Alzheon published 10 peer reviewed scientific publications on key discoveries in Alzheimer’s:
1. Identification of neurotoxic amyloid oligomers that initiate and drive Alzheimer’s pathogenesis
2. Biological diagnosis of Alzheimer’s using fluid biomarkers and imaging
3. Use of biomarkers to assess disease progression and efficacy of treatments
4. Role of APOE4 genotype in biology of Alzheimer’s

Phase 2 trial Biomarker Steering Committee: the top 3 experts

Kaj Blennow, MD, PhD Developed p-tau₁₈₁ biomarker for AD (on Aduhelm’s FDA label); Professor of Clinical Neurochemistry, University of Gothenburg, Sweden	Eric Reiman, MD Developed p-tau₂₁₇ biomarker for AD; Executive Director of Banner Alzheimer’s Institute, Chief Executive Officer of Banner Research, Phoenix	Philip Scheltens, MD, PhD Developed imaging & fluid AD biomarkers; Managing Partner of LSP Dementia Fund; Director of the Alzheimer Center, VU University, Amsterdam, Netherlands

Reflects current best internal estimates, subject to change; NDA – New Drug Application; sNDA – Supplemental New Drug Application; Phase 2 and Phase 3 studies continuing with Longterm Extension Studies (LTEs)